MARKET

LTRN

LTRN

Lantern Pharma Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.35
-0.15
-1.20%
Closed 16:00 08/05 EDT
OPEN
12.50
PREV CLOSE
12.50
HIGH
12.54
LOW
12.35
VOLUME
17.39K
TURNOVER
--
52 WEEK HIGH
15.44
52 WEEK LOW
11.51
MARKET CAP
74.48M
P/E (TTM)
-28.3127
1D
5D
1M
3M
1Y
5Y

LTRN News

More
Lantern Pharma reports Q2 results
Seeking Alpha · 07/30 11:40
Lantern Pharma Q2 EPS $(0.31) Up From $(0.32) YoY
Benzinga · 07/30 10:57
Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress
Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncolog
PR Newswire · 07/30 10:57
Stocks To Watch: Big Focus On Big Tech
Seeking Alpha · 07/25 12:26
Lantern Pharma to Host Second Quarter 2020 Operating and Financial Results Conference Call on July 30, 2020
Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development and, identify patients who will benefit from its portfolio of targeted oncolog
PR Newswire · 07/24 11:56
Lantern Pharma Establishes Manufacturing Network In Preparation For Its Phase 2 Clinical Trial For Treatment Of Non-Small Cell Lung Cancer And Phase 1 Clinical Trial For Solid Tumors And Glioblastoma
Benzinga · 07/20 11:56
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. 
Benzinga · 07/06 12:56
Lantern Pharmas Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Companys Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction
GlobeNewswire · 06/29 13:45

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About LTRN

Lantern Pharma Inc. is a clinical stage biotechnology company. The Company is focused on developing oncology therapies. It uses its artificial intelligence (AI) platform, RADR, which includes data points, and uses big data analytics to uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that benefits from its compounds. Its portfolio consists of three compounds: LP-100, LP-300 and LP-184. The Company is developing LP-100 for metastatic, castration-resistant, prostate cancer (mCRPC). LP-300 is a small molecule with cysteine modifying activity on select protein. LP-184, is in a preclinical translational ex vivo study using fresh human biopsies. LP-184 is an alkylating agent with nanomolar potency that preferentially damages deoxyribonucleic acid (DNA) in cancer cells that overexpress certain biomarkers.
More

Webull offers kinds of Lantern Pharma Inc. stock information, including NASDAQ:LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.